Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men

C.J. Hukshorn, W.H.M. Saris, M.S. Westerterp-Plantenga, A.R. Farid, F.J. Smith, L.A. Campfield

Research output: Contribution to journalArticleAcademicpeer-review

142 Citations (Scopus)
122 Downloads (Pure)

Abstract

To assess the biological activity and tolerability of pegylated recombinant native human leptin (PEG-OB), 30 obese men (mean body mass index, 33.9 kg/m(2)) were randomized to a double-blind treatment with weekly sc injections of 20 mg PEG-OB or placebo for 12 weeks, in addition to a hypocaloric diet (deficit, 2 MJ/day). Body composition, energy expenditure, and metabolic parameters were measured before and after treatment. PEG-OB was generally well tolerated based on adverse event reports, lab values, and vital signs. Weekly sc PEG-OB led to sustained serum concentrations of PEG-OB and leptin throughout treatment. No significant differences in the delta or percent weight loss, percent body fat, sleeping metabolic rate, or respiratory quotient mere observed between the PEG-OB and placebo groups. Percent change in serum triglycerides from baseline was significantly correlated with body weight loss in the PEG-OB group, but not in the placebo group. Although larger reductions in serum triglycerides were observed in the PEG-OB group compared with the placebo group, these differences were not statistically significant. We concluded that weekly injection of PEG-OB leads to sustained serum concentration of PEG-OB and leptin throughout the 12-week treatment period and is generally well tolerated. The trends observed in serum triglycerides suggest that a weekly 20-mg sc treatment with PEG-OB may have biological effects in obese men.
Original languageEnglish
Pages (from-to)4003-4009
Number of pages7
JournalJournal of Clinical Endocrinology & Metabolism
Volume85
Issue number11
DOIs
Publication statusPublished - 1 Jan 2000

Cite this

Hukshorn, C. J., Saris, W. H. M., Westerterp-Plantenga, M. S., Farid, A. R., Smith, F. J., & Campfield, L. A. (2000). Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. Journal of Clinical Endocrinology & Metabolism, 85(11), 4003-4009. https://doi.org/10.1210/jc.85.11.4003